^
    10d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    17d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    17d
    CDZR123C12101: TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC) (2025-521873-15-00)
    P1/2, N=54, Recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    abiraterone acetate • Nubeqa (darolutamide) • tulmimetostat (DZR123)
    24d
    Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=36 --> 24 | Trial completion date: Jan 2030 --> Jan 2029 | Trial primary completion date: Feb 2028 --> Feb 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    tulmimetostat (DZR123)
    1m
    EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=66, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • tulmimetostat (DZR123)
    3ms
    TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)
    P1/2, N=203, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • Nubeqa (darolutamide) • tulmimetostat (DZR123)
    5ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    5ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    5ms
    TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)
    P1/2, N=203, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    abiraterone acetate • Nubeqa (darolutamide) • tulmimetostat (DZR123)
    9ms
    CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Lan Coffman | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial primary completion date • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    carboplatin • tulmimetostat (DZR123)
    10ms
    FIH: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1/2, N=275, Recruiting, Novartis Pharmaceuticals | N=210 --> 275 | Trial completion date: Mar 2026 --> Feb 2030 | Trial primary completion date: Dec 2025 --> Feb 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    MSI-H/dMMR • ARID1A mutation
    |
    Xtandi (enzalutamide) • tulmimetostat (DZR123)
    11ms
    CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Lan Coffman | Trial completion date: Aug 2028 --> Dec 2028 | Trial primary completion date: May 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    carboplatin • tulmimetostat (DZR123)